J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as ...

Dr. Antoni Vilaseca Cabo discusses using an intravesical drug delivery system to continuously administer the FGFR inhibitor ...

A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs.

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association ...

Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in ...

National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50; Many respondents report undergoing ...

For five decades, scientists have known about a notorious cancer-causing enzyme called SRC. But they always assumed it only ...

Now, researchers at the University of California, San Francisco (UCSF), have discovered that Src also appears like a flag on the surface of bladder, colorectal, breast, pancreatic, and probably many ...

India, March 17 -- Can the human body produce vitamin B2? No, the human body cannot produce vitamin B2 (riboflavin) on its own. Without enough riboflavin, the body cannot make the molecules needed to ...

A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?